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Abstract
Background: Patients undergoing general anesthesia and mechanical ventilation during major abdominal surgery
commonly develop pulmonary atelectasis and/or hyperdistention of the lungs. Recent studies show benefits of
lung-protective mechanical ventilation with the use of low tidal volumes, a moderate level of positive end-expiratory
pressure (PEEP) and regular alveolar recruitment maneuvers during general anesthesia, even in patients with healthy
lungs. The purpose of this clinical trial is to evaluate the effects of intraoperative lung-protective mechanical ventilation,
using individualized PEEP values, on postoperative pulmonary complications and the inflammatory response.
Methods/design: A total number of 40 patients with bladder cancer undergoing open radical cystectomy and urinary
diversion (ileal conduit or orthotopic bladder substitute) will be enrolled and randomized into a study (SG) and a control
group (CG). Standard lung-protective ventilation with a PEEP of 6 cmH2O will be applied in the CG and an optimal PEEP
value determined during a static pulmonary compliance (Cstat)-directed PEEP titration procedure will be used in the SG.
Low tidal volumes (6 mL/Kg ideal bodyweight) and a fraction of inspired oxygen of 0.5 will be applied in both groups.
After surgery both groups will receive standard postoperative management. Primary endpoints are postoperative
pulmonary complications and serum procalcitonin kinetics during and after surgery until the third postoperative day.
Secondary and tertiary endpoints will be: organ dysfunction as monitored by the Sequential Organ Failure Assessment
Score, in-hospital stay, 28-day and in-hospital mortality.
Discussion: This trial will assess the possible benefits or disadvantages of an individualized lung-protective mechanical
ventilation strategy during open radical cystectomy and urinary diversion regarding postoperative pulmonary
complications and the inflammatory response.
Trial registration: ClinicalTrials.gov, ID: NCT02931409. Registered on 5 October 2016.
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Background
Patients undergoing general anesthesia and mechanical
ventilation during major abdominal surgery commonly
develop pulmonary atelectasis and/or hyperinflation of
the lungs leading to complications either intraoperatively
or in the postoperative period, resulting in ventilator-
induced lung injury (VILI) [1, 2].
Lung-protective mechanical ventilation (LPV), by ap-
plying “low” tidal volumes (TV = 6 mL/Kg of ideal body-
weight, IBW), optimal positive end-expiratory pressure
(PEEP) and regular alveolar recruitment maneuvers
(ARM) in case of acute respiratory distress syndrome
(ARDS) have been shown to be advantageous in critically
ill patients. Recent studies have also shown positive re-
sults of LPV and regular ARM during general anesthesia
in patients with healthy lungs [3, 4]. The main advan-
tages of this strategy are improved gas exchange and
prevention of either pulmonary atelectasis or VILI [5–7].
However, the effects of applying an optimal level of
PEEP have not entirely been evaluated.
There are several types of PEEP titration methods such
as dead space fraction (Vds/Vt)-guided or static pulmon-
ary compliance (Cstat)-directed techniques [8–12].
Theoretically, in patients with healthy lungs, during
general anesthesia and mechanical ventilation, inad-
equate PEEP values may lead to decreased pulmonary
compliance and gas exchange disorders due to pulmon-
ary atelectasis and/or hyperinflation of the lungs. In our
clinical trial, optimal PEEP values will be determined
during a static pulmonary compliance-directed PEEP ti-
tration procedure to protect from hyperdistention, and
regular ARMs will be performed using the sustained air-
way pressure by the continuous positive airway pressure
(CPAP) method, applying 30 cmH2O of PEEP for 30 s,
to prevent atelectasis [5, 13, 14].
On the one hand major abdominal surgery induces an
inflammatory response that is necessary for postopera-
tive recovery (e.g., wound healing), but on the other
hand an overwhelming inflammatory response may also
lead to adverse events (AEs) such as organ dysfunction
[15–19]. Radical cystectomy is considered major surgery;
hence, there is an increased risk of postoperative compli-
cations. Inappropriate mechanical ventilation during
general anesthesia can also lead to an amplified inflam-
matory response, which theoretically may worsen the
postoperative outcome via several mechanisms. How-
ever, the relationship between LPV and the postoperative
inflammatory response after radical cystectomy has not
been investigated yet.
There is strong correlation between the degree of in-
flammatory response and serum procalcitonin (PCT)
concentrations [20, 21]; hence, there is some rationale in
the belief that monitoring the inflammatory response by
regular PCT measurements in the postoperative period
reflects the host response. Therefore, there is some ra-
tionale in monitoring PCT kinetics as an indicator of the
host inflammatory response.
The aim of this investigator-initiated, double-center,
single-blinded (subject), prospective, randomized con-
trolled trial is to evaluate the effects of intraoperative
LPV, applying an individually titrated optimal PEEP, on
postoperative pulmonary complications (PPC) and the
inflammatory response in patients undergoing radical
cystectomy and urinary diversion (ileal conduit or ortho-
topic bladder substitute). We hypothesized that optimiz-
ing intraoperative mechanical ventilation (incorporating
LPV, ideal PEEP and ARM) can attenuate the inflamma-
tory response as compared to conventional modes of
mechanical ventilation, and hence may result in im-
proved postoperative oxygenation, prevent the occur-
rence of VILI, and reduce the incidence of organ
dysfunction. These anticipated advantages may also im-
prove postoperative recovery and survival rates, shorten
in-hospital stay and reduce health care-related costs.
Methods/design
Objectives of the study
The main objectives of this trial are to compare the effects
of a standard LPV applying 6 cmH2O of PEEP to a LPV
using an individually titrated optimal PEEP on: (1) oxy-
genation and PPC, (2) the degree of inflammatory
response evaluated by early PCT kinetics (0, 2, 6, 12, 24,
48 and 72 h after surgical incision) and (3) to evaluate the
relationship between the degree of inflammation and post-
operative pulmonary and extrapulmonary complications.
Study endpoints
The primary outcome variables are PPC and PCT kinet-
ics. PPC are defined as new infiltrates or atelectasis on a
chest X-ray, abnormal breathing sounds on auscultation,
respiratory failure defined as PaO2/FiO2 < 300 or the
need for noninvasive or invasive ventilatory support
within the first three postoperative days. PCT kinetics
will be evaluated during and after surgery. Blood sam-
ples will be taken at 0, 2, 6, 12, 24, 48 and 72 h after sur-
gical incision. According to recent data it is expected
that PCT values will peak at approximately 24 h after
surgery and that they should decline by approximately
50% daily in the case of an uneventful postoperative
course. Therefore, in addition to the absolute values
the change between T0–T24–T48 will also be evalu-
ated [16, 22].
Secondary outcome variables are extrapulmonary
complications: incidence of circulatory failure, gastro-
intestinal and renal dysfunction, hematologic and coagu-
lation disorders and infection (Table 1).
Tertiary endpoints are intensive care unit (ICU) days,
in-hospital stay, in-hospital and 28-day mortality.
Ruszkai et al. Trials  (2017) 18:375 Page 2 of 9
Study design
This is an investigator-initiated, double-center, parallel-
group, single-blinded, interventional, prospective, ran-
domized controlled trial conducted at the Department of
Anesthesiology and Intensive Care of Péterfy Sándor Hos-
pital Budapest and at the Department of Anesthesiology
and Intensive Therapy of University of Szeged. The first
patient will be randomized in October 2016. This
protocol conforms to the Consolidated Standards of
Reporting Trials (CONSORT) guidelines. Figure 1
shows the Standard Protocol Items: Recommendation
for Interventional Trials (SPIRIT) schedule of enroll-
ment, interventions and assessments. The SPIRIT
2013 Checklist is given in Additional file 1.
Blinding, data collection, randomization and record-
keeping
This is a single-blinded (participant) study. Patient data,
intraoperative and postoperative measurements, fluid
balance, respiratory parameters, laboratory results and
clinical status (Sequential Organ Failure Assessment
(SOFA) score) will be collected onto Case Report Forms
(CRF). CRF and the patient evaluation chart will not be
assessed in front of the patient.
Participants will be randomized to the SG or CG in a ra-
tio of 1:1. Randomization will be carried out by a
computer-generated blocked randomization list with 10
blocks of four patients per block. Allocation will be stored
in sealed, opaque and numbered envelopes. Participants
will be included and allocated in numerical order.
All original records (CRF and relevant correspond-
ence) will be archived and secured for 15 years, and then
destroyed according to the hospital standards concern-
ing destruction of confidential information.
Selection of the participants
Patients with bladder cancer scheduled for open radical
cystectomy and urinary diversion will be screened and
recruited during routine perioperative assessment. Par-
ticipants fulfilling the inclusion criteria will be asked for
their signed informed consent. Withdrawal of consent
may be initiated by the participant at any time during
the trial.
Inclusion criteria are age over 18 years, patients with
bladder cancer undergoing radical cystectomy and urin-
ary diversion (ileal conduit or orthotopic bladder substi-
tute) and provision of signed informed consent.
Exclusion criteria are age below 18 years, American
Society of Anesthesiologists (ASA) physical status IV,
history of severe chronic obstructive pulmonary disease
(COPD, GOLD grades III or IV), history of severe or un-
controlled bronchial asthma, history of severe restrictive
pulmonary disease, pulmonary metastases, history of any
thoracic surgery, need for thoracic drainage before sur-
gery, renal replacement therapy prior to surgery, con-
gestive heart failure (NYHA grades III or IV), extreme
obesity (Body Mass Index, BMI > 35 Kg/m2) and lack of
patient’s consent.
Time course of the study
Preoperative assessment and admission
During standard institutional preoperative assessment,
the patient’s eligibility for radical cystectomy and urinary
diversion will be evaluated. Medical history, laboratory
and chest X-ray or computed tomography (CT) scan,
12-lead electrocardiogram (ECG), ASA physical status,
BMI, Respiratory Failure Risk Index (RFRI), nutritional
risk screening (NRS 2002 tool) and, if required (in case
of history of smoking or coronary artery disease), results
of spirometry, echocardiography and ergometry will be
recorded. Participants fulfilling the inclusion criteria will
be asked for their signed informed consent.
After admission to the Department of Urology (on
the day before surgery) a central venous catheter will
be placed, a blood sample will be taken from included
patients for baseline levels of PCT (T0), a chest X-ray
will be performed and, if there are no exclusion cri-
teria, patients will be randomized into one of the
Table 1 Secondary endpoints
Endpoint Time frame Detailed description
Circulatory failure 28 days Hypotension – MAP < 65 mmHg
Severe cardiac arrhythmia – 40/min
< HR > 150/min
ScvO2 < 70%
dCO2 > 7 mmHg
Serum lactate > 2 mmol/L
Severe metabolic acidosis
(actual bicarbonate < 18 mmol/L)
Acute coronary syndrome
Acute left ventricular failure
Pulmonary embolism
Cardiac arrest
Gastrointestinal
dysfunction
28 days Constipation
Ileus
Anastomotic leakage
Reoperation
Disorders of liver function
Renal dysfunction 28 days RIFLE criteria
Hematologic and
coagulation disorders
28 days Severe bleeding
Coagulopathy – INR > 1.5
Infection 28 days Any infection except from
pneumonia
MAP mean arterial pressure, HR heart rate, ScvO2 central venous oxygen
saturation, dCO2 central venous-to-arterial carbon dioxide gap, INR
International Normalized Ratio
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study groups. Patients will be given oral carbohydrate
loading (maltodextrin) 12, 8 and 2 h before surgery,
1000 mL of crystalloid solution will be given and
antimicrobial prophylaxis will be introduced using
ciprofloxacin and metronidazole 30 min before surgi-
cal incision. Antimicrobial prophylaxis will be contin-
ued for 72 h (2 × 400 mg ciprofloxacin and 3 ×
500 mg metronidazole per day). Deep vein thrombosis
prophylaxis will be carried out using low-molecular-
weight heparin (LMWH).
Intraoperative care
Before induction of anesthesia an epidural catheter and
an arterial cannula will be inserted for invasive arterial
blood pressure monitoring and blood gas sampling.
Immediately after induction of anesthesia and orotra-
cheal intubation, once a steady state has been reached
(Table 2), all patients will be submitted to an ARM using
the sustained airway pressure by the CPAP method, ap-
plying 30 cmH2O PEEP for 30 s. After ARM, PEEP will
be set to 6 cmH2O in the CG (“standard PEEP”) and
Fig. 1 Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) schedule of enrollment, interventions and assessments. DOS day
of surgery, POD postoperative day, SOFA Sequential Organ Failure Assessment, ICU intensive care unit
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LPV (TV = 6 mL/Kg IBW, FiO2 = 0.5) will be performed.
In the SG (“optimal PEEP”) PEEP will be determined
during a Cstat-directed decremental PEEP titration pro-
cedure. During surgery ARM will be repeated and arterial
and central venous blood gas samples (ABGs, CVBGs) will
be evaluated every 60 min. In case of decreased oxygen
saturation (SpO2 < 94%) rescue ARM will be performed
using a FiO2 of 1.0. PCT levels will be measured 2, 6, 12,
24, 48 and 72 h after surgical incision.
Arterial blood pressure, heart rate (HR) and end-tidal
carbon dioxide tension (EtCO2) will be monitored con-
tinuously. Cstat, airway resistance (Raw), Vds/Vt, core
temperature and train-of-four relaxometry data will be
recorded every 15 min.
During surgery, in cases of hypotension, intravenous
norepinephrine will be started to maintain mean arterial
pressure above 65 mmHg. For intraoperative fluid man-
agement patients will receive 3 mL/Kg/h of balanced
crystalloid solution until end of surgery. In cases of
bleeding, a 200-mL colloid (hydroxyethyl starch, HES)
solution bolus and crystalloid substitution will be given.
Packed red blood cell (PRBC) transfusion will be given
whenever the attending anesthetist feels it necessary.
Postoperative care
After extubation, patients will be admitted to the ICU.
ABGs and CVBGs will be collected and evaluated (pH,
base excess (BE), standard bicarbonate (stHCO3−),
ScvO2), PaO2/FiO2 and central venous-to-arterial carbon
dioxide gap (dCO2) will be calculated every 6 h until
72 h after surgery. On the first postoperative day (POD),
a chest X-ray will be performed and repeated on the fol-
lowing days if the development of pulmonary complica-
tions are suspected. The chest X-ray will be evaluated by
an independent, trained radiologist who will not be in-
volved in the study. Continuous epidural analgesia and
intermittent intravenously administered analgesia (para-
cetamol or metamizol) will be introduced, and evaluated
effective if a Numeric Pain Rating Scale (NPRS) score is
lower than 3 points.
During postoperative care, continuous intraabdominal
pressure (IAP) monitoring via a direct intraperitoneal
catheter, placed before closure of the abdominal wall,
will be performed to eliminate bias caused by the eleva-
tion of IAP.
Patients’ clinical progress and secondary endpoints will
be monitored by daily SOFA scores, laboratory and
physical examinations.
Postoperative hydration and vasopressor therapy will
be directed by MAP, ScvO2, dCO2 and arterial lactate
levels. PRBC units will be transfused if decreased
hemoglobin (Hb) levels result in tissue oxygenation
disorders or become symptomatic (hypotension, dizzi-
ness or weakness develop). Fresh frozen plasma will be
given if the prothrombin International Normalized Ratio
(INR) > 1.5. Platelet suspension units will be given ac-
cording to the Transfusion Guidelines of the Hungarian
National Blood Transfusion Service.
In both groups, patients will be allowed to drink clear
fluids immediately after surgery and the use of chewing
gum will be encouraged. Prokinetics and an oral liquid
diet using a drinking formula will be started on POD 1
and patients will begin active mobilization. The nasogas-
tric tube will be removed on the morning of POD 1.
From postoperative day 4 (POD 4 to POD 28, follow-up)
During the follow-up period, secondary endpoints, in-
hospital stay, 28-day and in-hospital mortality will also
be evaluated.
Figure 2 shows the CONSORT flowchart of the trial.
Study arms and assigned intraoperative interventions
A total number of 40 patients with bladder cancer sub-
mitted to general anesthesia and open radical cystec-
tomy and urinary diversion will be enrolled in this study.
An equal number of patients will be randomized into
the two groups.
Patients randomized into the SG group undergo an al-
veolar recruitment maneuver using the sustained airway
pressure by the CPAP method, applying 30 cmH2O
PEEP for 30 s followed by a decremental PEEP titration
procedure directed by Cstat. During the PEEP titration
procedure, PEEP will be decreased from 14 cmH2O by 2
cmH2O every 4 min, until a final PEEP of 6 cmH2O is
reached. On each level of PEEP, ABGs will be collected
and evaluated. Optimal PEEP is considered as the PEEP
value resulting the highest possible Cstat measured by
the ventilator. After the PEEP titration procedure, lung-
protective mechanical ventilation will be performed
using optimal PEEP and low tidal volumes and ARM will
be performed every 60 min.
Patients randomized into the CG group will undergo
an alveolar recruitment maneuver using the sustained
airway pressure by the CPAP method, applying 30
cmH2O PEEP for 30 s followed by low-tidal-volume
LPV using a PEEP value of 6 cmH2O and ARM will be
repeated every 60 min.
Table 2 Steady state after induction of anesthesia
Parameter Value
Hemodynamics Mean arterial pressure 65 mmHg <MAP < 90 mmHg
Heart rate 50/min < HR < 100/min
Ventilation SpO2 ≥96%
EtCO2 35–40 mmHg
Anesthetics EtSevo 1.0 MAC
MAP mean arterial pressure, HR heart rate, SpO2 peripheral capillary oxygen
saturation, EtCO2 end-tidal carbon dioxide partial pressure, EtSevo end-tidal
sevoflurane concentration, MAC minimal alveolar concentration
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Data monitoring
Data monitoring will be performed centrally for quality
control purposes by an external, independent physician,
who will not be involved in the study. Monitoring will
evaluate the progress of the study and verify the accur-
acy and completeness of the data recording (CRF, source
data, Informed Consent Forms and outcome variables).
Statistics
Data will be analyzed by the research team in collabor-
ation with a medically versed biostatistician after com-
pletion of the trial. There will be no interim analysis.
Statistical analysis will be conducted on an intention-to-
treat basis. IBM SPSS 20.0 statistical software will be
used for analysis.
Fig. 2 Consolidated Standards of Reporting Trials (CONSORT) flowchart. PEEP positive end-expiratory pressure, PCT procalcitonin, ABGs arterial blood
gas sample, CVBGs central venous blood gas sample, Cstat static pulmonary compliance, Vds/Vt dead space fraction, Raw airway resistance, MAP mean
arterial pressure, ARM alveolar recruitment maneuver, PRBC packed red blood cell, FFP fresh frozen plasma, IAP intraabdominal pressure
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It is expected that the majority of source data will be
recorded onto CRF; nonetheless, before starting the data
analysis, the mechanism and pattern of missing data will
be evaluated and these findings will be used to deter-
mine whether they have had an impact on the statistical
analysis and results and how they can be managed.
Data distribution will be tested by the Kolmogorov-
Smirnov analysis. Normally distributed data will be pre-
sented as mean and standard deviation (SD) and skewed
data as median (interquartile range). Comparing related
samples, the paired and unpaired t test will be used for
normally distributed data and the Wilcoxon signed rank
test and Mann-Whitney U test for skewed data. Differ-
ences in proportions will be evaluated using the Fisher’s
exact test, and risk ratio with associated 95% confidence
interval (CI). Analysis of the primary endpoint (PPC)
will be carried out by the unpaired Student’s t test (95%
CI). A two-way, repeated-measures analysis of variance
(two-way RM ANOVA) will be used to compare the
groups’ serum PCT levels. The relationship between
PCT levels and organ dysfunctions will be evaluated
using the Pearson correlation. Statistical analysis of SOFA
scores, ICU days, in-hospital stay, in-hospital and 28-day
mortality data of groups will be implemented by the chi-
square test. A P value < 0.05 will be considered significant.
Adverse events and interruption of the trial
Every patient included in the trial will receive daily visits
from an intensive care therapist and urologist in charge
from POD 1 until leaving the hospital. During ICU stay,
and if necessary on the intermediate care unit, all pa-
tients will be continuously monitored. The study nurse
will be responsible for collecting blood samples and will
record relevant required data onto CRF. During the out-
of-hospital follow-up period (until POD 28) patients’
progress, particularly deterioration will be checked by
daily phone-call visits.
The investigators will monitor the patients for any ad-
verse events (AEs), which are defined as severe or pro-
longed hypotension (systolic blood pressure < 90 mmHg)
and significant cardiac arrhythmias associated with the
PEEP titration procedure. AEs will be documented on
the CRF and the principal investigator will be informed.
Serious adverse events (SAEs) are defined as severe baro-
trauma leading to pneumothorax, significant prolongation
of hospitalization, persistent or significant disability or in-
capacity, and severe deterioration (life-threatening state or
even death) associated with the PEEP titration procedure.
All treatment-related SAEs will be recorded and reported
to the Hungarian Scientific and Medical Research Council
Ethics Committee and the Local Ethics Committees. If any
SAEs occur, the trial will be interrupted and an investiga-
tion will be performed.
Duration of the trial
The annual number of open radical cystectomy and
urinary diversion is around 100 in the two study centers.
Recruitment of the participants is expected within
18 months. The final data collection and estimated com-
pletion date of the trial is March 2018.
Discussion
This investigator-initiated, pragmatic, interventional, pro-
spective, randomized controlled trial will assess the
possible benefits and disadvantages of an individualized
lung-protective mechanical ventilation strategy during
open radical cystectomy and urinary diversion as indicated
mainly by PPC and the inflammatory response.
PPC can develop after major abdominal surgery. Im-
paired gas exchange may lead to secondary disorders
(delayed return of gastrointestinal function, renal dys-
function, cardiac disorders, etc.) resulting in prolonged
hospitalization time and increased cost of hospital care
[15–17]. The impact of an inappropriate intraoperative
mechanical ventilation-caused inflammatory response –
both systemic and intrapulmonary –, on these complica-
tions is still uncertain.
Surgery induces an inflammatory response that is neces-
sary for postoperative recovery [18–21]. Inappropriate
mechanical ventilation can also cause an inflammatory re-
sponse, which can lead to AEs such as pulmonary compli-
cations and distant organ dysfunction. Applying an
individualized lung-protective ventilatory strategy during
general anesthesia may reduce the degree of inflammation
and decrease the incidence of pulmonary and extrapul-
monary complications in the postoperative period, thereby
contributing to shorter hospitalization time and reduced
cost of hospital care [3–5].
Radical cystectomy and urinary diversion is considered
major surgery with an operating time lasting for several
hours. This gives the potential for inappropriate intraop-
erative ventilatory management causing further harm by
exacerbating the surgery-induced inflammatory re-
sponse, hence causing more postoperative complica-
tions. Titrating PEEP and performing regular ARMs
during the anesthesia of these patients certainly has a
strong pathophysiological rationale with potential bene-
fits as indicated by recent clinical trials [4–7, 14], but
this strategy is also cumbersome, time consuming and,
due to the numerous blood gas samplings required, may
be costly. Therefore, testing our hypothesis in a clinical
study is necessary to answer these questions.
The potential implications of our results can further
improve our knowledge on the effects of optimal intra-
operative ventilatory strategies and, in the case of posi-
tive results, these may not only be applicable to patients
with bladder cancer undergoing radical cystectomy and
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urinary diversion, but presumably to all patients under-
going similar types of major abdominal surgery.
Trial status
The trial is ongoing.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents. (DOCX 52 kb)
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